|Articles|July 28, 2009
Retina Roundtable Session 3
Advertisement
Subscribe
In this third session, the physicians discuss how they communicate to their patients the increased risk of stroke that may be associated with dosing of anti-VEGF agents.
Participants include:
Return to
Return to
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
2
Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap
3
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
4
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
5






















